JST-TfR09
JST‑TfR09 (PPMX‑T003) is a human monoclonal antibody (mAb) targeting transferrin receptor 1 (TfR1/CD71). JST‑TfR09 blocks the binding of transferrin to TfR1, inhibits TfR1 internalization, and suppresses cellular iron uptake. JST‑TfR09 triggers ferritin degradation via activating the autolysosomal system, promotes ROS production and lipid peroxidation, and ultimately induces ferroptosis. JST‑TfR09 exhibits cytotoxicity toward human erythroblasts differentiated from hematopoietic stem cells. JST-TfR09 can be used in leukemia research. Recommended isotype control: Human IgG1 lambda, Isotype Control (HY-P99992).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.59%
- 분자량:145.79 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
Human IgG1 lambda
Human
CD71
JST-TfR09 (10 ng/well-200 ng; 48 h) reduces viability of MT2, Su9T1, and KK1, and this cell death is inhibited by ferrostatin-1[1].
JST-TfR09 (100 ng/mL; 48 h) downregulates TFR1, FTH1, and FTL, upregulates IRP2 and NCOA4, and induces lysosome-dependent ferritin degradation and autophagy in ED, KK1, and MT2 ATLL cell lines[1].
JST-TfR09 (100 ng/mL; 48 h) increases intracellular ferrous iron, ROS, and lipid peroxidation (MDA) levels, key hallmarks of ferroptosis, in Su9T1, MT2, ST1, SO4, KK1, and ED ATLL cell lines and MOLT4, JURKAT T-ALL cell lines[1].
JST-TfR09 induces in vitro toxicity to human erythroblasts differentiated from CD34 hematopoietic stem cells at concentrations greater than 156 ng/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:adult T-cell leukemia/lymphoma (ATLL) cell lines (ED, Su9T01, S1T, KK1, KOB, ST1), HTLV-1-transformed human T-cell lines (MT2, HUT102), cutaneous T-cell lymphoma (CTCL) cell lines (HUT78, HH)
-
Concentration:10 ng/well; 200 ng; 100 ng/mL
-
Incubation Time:48 h
-
Result:Reduced the viability of MT2, Su9T1, and KK1 ATLL cell lines to 40-60% relative to controls.
Increased cell viability to almost 80% in MT2, Su9T1, and KK1 ATLL cell lines when co-treated with ferrostatin-1.
-
Cell Line:ATLL cell lines (ED, KK1, MT2)
-
Concentration:100 ng/mL;
25 μM Aloxistatin (HY-100229) + 50 μM Pepstatin A (HY-P0018) (pretreatment);
10 μM MG132 (HY-13259) (pretreatment) -
Incubation Time:48 h (JST-TfR09); 24 h (pretreatment prior to JST-TfR09)
-
Result:Decreased TFR1, FTH1, and FTL protein levels in ED and KK1 cells.
Increased IRP2 and NCOA4 protein levels in ED and KK1 cells.
Prevented JST-TfR09-induced ferritin degradation in cells pretreated with lysosomal inhibitors, while proteasomal inhibitor pretreatment did not.
Increased LC3-II expression relative to LC3-I in cells, indicating autophagy activation, which was blocked by lysosomal inhibitor co-treatment.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
분자량 145.79 kDa
-
Color Colorless to light yellow
-
SMILES
[JST-TfR09]
-
Synonyms
PPMX-T003; TSP-A18
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Fauzi YR, et al. Anti-transferrin receptor antibody (JST-TFR09/PPMX-T003) induces ferroptosis in adult T-cell leukemia/lymphoma (ATLL) cells. Biochem Biophys Res Commun. 2025;756:151564. [Content Brief]
[2]. Daniels-Wells TR, et al. Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma. Cancers (Basel). 2023;15(6):1816. Published 2023 Mar 17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JST-TfR09 Related Classifications
HY-P991381 Related Classifications
Powered by Bioz